ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024
Preclinical Characterization of DPI-4452: A
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Guideline
- Progress in the application ofAnnals of nuclear medicine · 2026Review
- Cyclic Peptides in Modern Drug Discovery: Trends and Therapeutic Directions.Journal of medicinal chemistry · 2026Review
- [Chemical & biomedical imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Carbonic Anhydrase IX-Targeted Molecular Probe for Positron Emission Tomography Imaging of Clear Cell Renal Cell Carcinoma.Chemical & biomedical imaging · 2026Article
- Application of carbonic anhydrase IX-targeted radiopharmaceuticals in the diagnosis and treatment of clear cell renal cell carcinoma (Review).Oncology letters · 2026Review
- Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.Case reports in urology · 2026Article
- Structure-based redesign enables clinical translation of CAIX-targeted theranostics in clear cell renal cell carcinoma.Theranostics · 2026Article
- Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges.Frontiers in pharmacology · 2026Review
- Recent Advances in Cyclic Peptide-Based Therapeutic Strategies for Renal Cell Carcinoma: A Focused Review.Drug design, development and therapy · 2026Review
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Review
- "Precision on Two Wheels"─Structural Refinement ofJournal of medicinal chemistry · 2025Article
- Peptide-Based Biomaterials as a Promising Tool for Cancer Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Synthesis and Construction of I-124 Labeled Small Molecular Probe for Noninvasive PET Imaging of CAIX Expression.Molecular imaging and biology · 2025Article
- Biomarkers in advanced renal cell carcinoma: current practice and future directions.Current opinion in oncology · 2025Review
- Comparison of carbonic anhydrase-IX-targeted trifunctional radioligands between linear- and branched-chain arrangements.Frontiers in nuclear medicine · 2025Article
- CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.American journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The membrane protein carbonic anhydrase IX (CAIX) is highly expressed in many hypoxic or von Hippel-Lindau tumor suppressor-mutated tumor types. Its restricted expression in healthy tissues makes CAIX an attractive diagnostic and therapeutic target. DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, allowing radionuclide chelation for theranostic purposes. Here, we report CAIX expression in multiple tumor types and provide in vitro and in vivo evaluations of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.